EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway

Licheng Du iD, Wenjia Ren, Linjun Liu, Haojia Zhu, Ke Xu, Yubai Zhou

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0316432 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Licheng Du und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, College of Chemistry & Life Science, Beijing University of Technology, Chaoyang, Beijing, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Proto-Oncogene Proteins c-akt, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer, characterized by a high incidence in late stages, high mortality rate, and poor prognosis. Src Homology 2 Domain Containing Protein 5 (SH2D5) is a mammalian-specific, uncharacterized scaffolding protein, and its role in LUAD remains unclear. In the present study, we investigated the function and potential mechanisms of SH2D5 in the progression of LUAD. We found aberrant expression of SH2D5 in LUAD tissues and cells, and its high expression is closely associated with poor prognosis in LUAD patients. Through loss-of-function and gain-of-function experiments, we revealed that overexpression of SH2D5 promotes the proliferation and migration abilities of lung adenocarcinoma cells. Gene set enrichment analysis (GSEA) revealed that SH2D5 positively regulates the epithelial-mesenchymal transition (EMT) process in lung adenocarcinoma cells. Additionally, we found that regulating the expression of SH2D5 influenced the phosphorylation levels of AKT, and the rescue experiments with AKT pathway activators/inhibitors partially reversed the tumor progression and EMT processes induced by SH2D5. In summary, our study demonstrated that SH2D5 promotes the migration and EMT process of LUAD cells through the AKT signaling pathway, suggesting that SH2D5 may serve as a crucial potential target for the treatment of metastatic LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionProto-Oncogene Proteins c-aktAdenocarcinoma of LungLung NeoplasmsSignal TransductionCell MovementCell ProliferationHumansCell Line, TumorAnimalsGene Expression Regulation, NeoplasticMiceNeoplasm MetastasisPrognosisMice, NudeMaleFemaleA549 Cells

Substanzen

Proto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • Department of Biology, College of Chemistry & Life Science, Beijing University of Technology, Chaoyang, Beijing, China.
  • NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, China CDC, Changping, Beijing, China.

ORCID-Profile: Licheng Du

Zitieren

APA

Du, L., Ren, W., Liu, L., Zhu, H., Xu, K., & Zhou, Y. (2024). SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0316432

Vancouver

Du L, Ren W, Liu L, Zhu H, Xu K, Zhou Y. SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway. PLOS ONE. 2024. doi:10.1371/journal.pone.0316432

BibTeX
@article{Du2024,
  author = {Du, Licheng and Ren, Wenjia and Liu, Linjun and Zhu, Haojia and Xu, Ke and Zhou, Yubai},
  title = {SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0316432}
}
Kostenlos starten →